Sofosbuvir induced leucocytoclasic vasculitis: a case report

被引：3

作者：

Campione, Elena ^{[1
]}

Dattola, Annunziata ^{[1
]}

Di Prete, Monia ^{[2
]}

Di Paolo, Daniele ^{[3
]}

Ferlosio, Amedeo ^{[2
]}

Orlandi, Augusto ^{[2
]}

Bianchi, Luca ^{[1
]}

机构：

[1] Univ Roma Tor Vergata, Dept Dermatol, Viale Oxford 81, I-00133 Rome, Italy

[2] Univ Roma Tor Vergata, Dept Anat Pathol, Viale Oxford 81, I-00133 Rome, Italy

[3] Dept Internal Med, Hepatol Unit, Rome, Italy

来源：

BMC DERMATOLOGY | 2019年 / 19卷

关键词：

Sofosbuvir; Hepatitis C; Leukocytoclasic vasculitis; CHRONIC HEPATITIS-C; MIXED CRYOGLOBULINEMIA; VIRUS; THERAPIES; RIBAVIRIN; EFFICACY; SAFETY; DRUG; HCV;

D O I：

10.1186/s12895-019-0086-4

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

BackgroundWe describe a case of leucocytoclasic vasculitis induced by Sofosbuvir and its disappearence after the end of the therapy. The hepatitis C virus, firstly described in 1989, is a major global health problem, with high morbidity and mortality. We observed a temporal relationship between the treatment and the onset of vasculitis. We emphasize the multidisciplinary approach to the patients with liver disease to improve the quality of life of these patients.Case presentationA 53-year-old Caucasian man with a history of hepatitis C virus genotype 1 infection was examined at our Department of Dermatology for the occurrence of palpable purpura. The patient referred that the first appearance of the dermatoses was about one month after initiation of therapy with Sofosbuvir for hepatitis C.ConclusionsVasculitis appeared after the beginning of Sofosbuvir and, even though it was treated with different medications proved to be effective, it disappeared only after the conclusion of the therapy, giving a strong evidence to be a drug eruption.

引用

页数：4

共 18 条

[1]

Ahmad Youssef K, 2017, Hosp Pharm, V52, P294, DOI 10.1310/hpj5204-294

[2]

Aniszewska Malgorzata, 2010, Przegl Lek, V67, P9

[3]

[Anonymous], 2010, VIR HEP 63 WORLD HLT

[4] Tissue eosinophilia as an indicator of drug-induced cutaneous small-vessel vasculitis [J].

Bahrami, S ;

Malone, JC ;

Webb, KG ;

Callen, JP .

ARCHIVES OF DERMATOLOGY, 2006, 142 (02) :155-161

[5] Extrahepatic manifestations of chronic hepatitis C virus infection [J].

Cacoub, Patrice ;

Comarmond, Cloe ;

Domont, Fanny ;

Savey, Lea ;

Desbois, Anne C. ;

Saadoun, David .

THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE, 2016, 3 (01) :3-14

[6] ISOLATION OF A CDNA CLONE DERIVED FROM A BLOOD-BORNE NON-A, NON-B VIRAL-HEPATITIS GENOME [J].

CHOO, QL ;

KUO, G ;

WEINER, AJ ;

OVERBY, LR ;

BRADLEY, DW ;

HOUGHTON, M .

SCIENCE, 1989, 244 (4902) :359-362

[7]

Gadde Shilpa, 2016, World J Nephrol, V5, P547

[8] A Novel Promising Therapeutic Option Against Hepatitis C Virus: An Oral Nucleotide NS5B Polymerase Inhibitor Sofosbuvir [J].

Gentile, I. ;

Borgia, F. ;

Buonomo, A. R. ;

Castaldo, G. ;

Borgia, G. .

CURRENT MEDICINAL CHEMISTRY, 2013, 20 (30) :3733-3742

[9] Finally sofosbuvir: an oral anti-HCV drug with wide performance capability [J].

Kayali, Zeid ;

Schmidt, Warren N. .

PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 :387-398

[10] Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naive and treatment-experienced patients [J].

Liu, Xi ;

Wang, Yawen ;

Zhang, Guanjun ;

Li, Na ;

Zhu, Qianqian ;

Chang, Hongyun ;

Han, Qunying ;

Lv, Yi ;

Liu, Zhengwen .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2014, 44 (02) :145-151

← 1 2 →